Memantine

• UNSPSC Description:

  Memantine is an orally active, noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist. Memantine can be used for the research of moderate-to-severe Alzheimer's disease (AD)[1][2][3].

• Target Antigen:

  iGluR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel;Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/memantine.html

• Purity:

  99.81

• Solubility:

  DMSO : 10 mg/mL (ultrasonic)

• Smiles:

  N[C@]12C[C@@]3(C)C[C@](C2)(C)C[C@@H](C1)C3

• Molecular Weight:

  179.30

• References & Citations:

  [1]Marotta G, et al. Memantine Derivatives as Multitarget Agents in Alzheimer's Disease. Molecules. 2020;25(17):4005. Published 2020 Sep 2. |[2]Pinho J, et al. Enhanced LTP in aged rats: Detrimental or compensatory?. Neuropharmacology. 2017;114:12-19. |[3]Moriguchi S, et al. Memantine Improves Depressive-like Behaviors via Kir6.1 Channel Inhibition in Olfactory Bulbectomized Mice. Neuroscience. 2020;442:264-273. Biomedicines. 2022, 10(10), 2358.|Pharmacol Res Perspect. 2021 Oct;9(5):e00879.|Biomark Res. 2023 Aug 8;11(1):74.|Folia Neuropathol. 2023 Mar;61:1-12.|Neurochem Res. 2018 Oct;43(10):2008-2015.|Neuropharmacology. 2020 Dec 17;184:108443.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  Launched

• CAS Number:

  9007-83-4